Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Sep 20, 2024

Keywords

ClinConnect Summary

This clinical trial, called DOTABREAST, is studying how well a specific imaging test, called PET scan using 68Ga-DOTATOC, can detect somatostatin receptors in women with metastatic breast cancer. These receptors might help doctors understand more about the cancer and how it spreads, especially in patients who have already received some initial treatment. The trial is currently looking for female participants aged 18 and older who have metastatic breast cancer with certain characteristics, such as having completed at least one line of systemic therapy and having specific types of lesions visible in previous PET scans.

If you decide to participate, you'll undergo a PET scan with 68Ga-DOTATOC within 21 days of a previous PET scan that uses a different imaging agent. This study does not involve any new treatments, but rather focuses on the imaging aspect to gather important information about your cancer. It's important to know that participants need to provide consent and be affiliated with social security. This trial aims to improve how doctors can track and understand metastatic breast cancer, potentially leading to better treatment strategies in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age over 18
• • Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer
• • Patient labeled on the primary lesion ER+HER2- (20)
• • Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan
• • Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan
• • No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan.
• • Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan
• • Person affiliated to or benefiting from social security
• • Person who has given written informed consent
• Exclusion Criteria:
• • Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor)
• • Known allergy to 68Ga-DOTATOC or its excipients
• • Subject refusing to sign the consent to participate
• • Minor subject
• • Subject excluded from another study
• • Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP)
• • Subject cannot be contacted in case of emergency